Tumor Biology

, Volume 35, Issue 11, pp 10987–10991 | Cite as

The Axin2 rs2240308 polymorphism and susceptibility to lung cancer in a Chinese population

  • Dan Liu
  • Ling Li
  • Yuguang Yang
  • Wentao Liu
  • Jin Wu
Research Article


Axis inhibition protein 2 (Axin2) is a negative regulator of the canonical Wnt/β-catenin signaling pathway, and functions as a tumor suppressor in a number of human cancers. Previous pilot studies have suggested an association between Axin2 exon1 148 (rs2240308) SNP polymorphism and risk for lung cancer. In the present study, we aimed to investigate the Axin2 exon1 148 polymorphism and its association with lung cancer susceptibility in Han Chinese population. The Axin2 exon1 148 SNP was genotyped in 555 controls and 520 lung cancer patients using TaqMan SNP Genotyping Assays. Unconditional logistic regression analysis was used to calculate adjusted odds ratios (ORs) and 95 % confidence intervals (CIs). We observed that the genotype frequencies of TC, TT, and CC were significantly different between controls and cases (χ 2 = 6.849, P = 0.03256, df = 2). Subjects carrying T allele (TC + TT genotypes) had decreased susceptibility to lung cancer as compared to those carrying CC genotype (OR = 0.733, 95 % CI = 0.5726–0.9393, P = 0.01382). No significant association was found between rs2240308 polymorphism and histological subtypes of lung cancers. Findings from this study suggest that Axin2 exon1 T148C polymorphism (rs2240308) contributes to increased susceptibility to lung cancer in Chinese population. This further implicates Axin2 as a lung cancer-related gene.


Axin2 Polymorphism Lung cancer Chinese population 



The study was supported by the project of scientific and technological research of the Department of education of Heilongjiang Province in 2012 (project number: 12521317). The funding source had no role to play in the study design, the collection and interpretation of the data, writing of the report, or decision to submit this paper for publication.

Conflict of interest



  1. 1.
    Bunn Jr PA. Worldwide overview of the current status of lung cancer diagnosis and treatment. Arch Pathol Lab Med. 2012;136:1478–81.PubMedCrossRefGoogle Scholar
  2. 2.
    He B, Jablons DM: Wnt signaling in stem cells and lung cancer. Ernst Schering Foundation symposium proceedings 2006: 27–58.Google Scholar
  3. 3.
    Zeng L, Fagotto F, Zhang T, Hsu W, Vasicek TJ, Perry 3rd WL, et al. The mouse fused locus encodes Axin, an inhibitor of the Wnt signaling pathway that regulates embryonic axis formation. Cell. 1997;90:181–92.PubMedCrossRefGoogle Scholar
  4. 4.
    Nakamura T, Hamada F, Ishidate T, Anai K, Kawahara K, Toyoshima K, et al. Axin, an inhibitor of the Wnt signalling pathway, interacts with beta-catenin, GSK-3beta and APC and reduces the beta-catenin level. Genes to Cells : Devoted Mol Cell Mech. 1998;3:395–403.CrossRefGoogle Scholar
  5. 5.
    Huang H, He X. Wnt/beta-catenin signaling: new (and old) players and new insights. Curr Opin Cell Biol. 2008;20:119–25.PubMedCentralPubMedCrossRefGoogle Scholar
  6. 6.
    Salahshor S, Woodgett JR. The links between axin and carcinogenesis. J Clin Pathol. 2005;58:225–36.PubMedCentralPubMedCrossRefGoogle Scholar
  7. 7.
    Akiyama T. Wnt/beta-catenin signaling. Cytokine Growth Factor Rev. 2000;11:273–82.PubMedCrossRefGoogle Scholar
  8. 8.
    Konigshoff M, Eickelberg O. WNT signaling in lung disease: a failure or a regeneration signal? Am J Respir Cell Mol Biol. 2010;42:21–31.PubMedCrossRefGoogle Scholar
  9. 9.
    Mazieres J, He B, You L, Xu Z, Jablons DM. Wnt signaling in lung cancer. Cancer Lett. 2005;222:1–10.PubMedCrossRefGoogle Scholar
  10. 10.
    Ueda M, Gemmill RM, West J, Winn R, Sugita M, Tanaka N, et al. Mutations of the beta- and gamma-catenin genes are uncommon in human lung, breast, kidney, cervical and ovarian carcinomas. Br J Cancer. 2001;85:64–8.PubMedCentralPubMedCrossRefGoogle Scholar
  11. 11.
    Tseng RC, Lin RK, Wen CK, Tseng C, Hsu HS, Hsu WH, et al. Epigenetic silencing of AXIN2/betaTrCP and deregulation of p53-mediated control lead to wild-type beta-catenin nuclear accumulation in lung tumorigenesis. Oncogene. 2008;27:4488–96.PubMedCrossRefGoogle Scholar
  12. 12.
    Liu W, Dong X, Mai M, Seelan RS, Taniguchi K, Krishnadath KK, et al. Mutations in AXIN2 cause colorectal cancer with defective mismatch repair by activating beta-catenin/TCF signalling. Nat Genet. 2000;26:146–7.PubMedCrossRefGoogle Scholar
  13. 13.
    Kanzaki H, Ouchida M, Hanafusa H, Yano M, Suzuki H, Aoe M, et al. Single nucleotide polymorphism of the AXIN2 gene is preferentially associated with human lung cancer risk in a Japanese population. Int J Mol Med. 2006;18:279–84.PubMedGoogle Scholar
  14. 14.
    Gunes EG, Pinarbasi E, Pinarbasi H, Silig Y. Strong association between lung cancer and the AXIN2 polymorphism. Mol Med Rep. 2009;2:1029–35.PubMedGoogle Scholar
  15. 15.
    Lee E, Salic A, Kruger R, Heinrich R, Kirschner MW. The roles of APC and Axin derived from experimental and theoretical analysis of the Wnt pathway. PLoS Biol. 2003;1:E10.PubMedCentralPubMedCrossRefGoogle Scholar
  16. 16.
    Behrens J, Jerchow BA, Wurtele M, Grimm J, Asbrand C, Wirtz R, et al. Functional interaction of an axin homolog, conductin, with beta-catenin, APC, and GSK3beta. Science. 1998;280:596–9.PubMedCrossRefGoogle Scholar
  17. 17.
    Anderson CB, Neufeld KL, White RL. Subcellular distribution of Wnt pathway proteins in normal and neoplastic colon. Proc Natl Acad Sci U S A. 2002;99:8683–8.PubMedCentralPubMedCrossRefGoogle Scholar
  18. 18.
    Leung JY, Kolligs FT, Wu R, Zhai Y, Kuick R, Hanash S, et al. Activation of AXIN2 expression by beta-catenin-T cell factor. A feedback repressor pathway regulating Wnt signaling. J Biol Chem. 2002;277:21657–65.PubMedCrossRefGoogle Scholar
  19. 19.
    Hughes TA, Brady HJ. Regulation of axin2 expression at the levels of transcription, translation and protein stability in lung and colon cancer. Cancer Lett. 2006;233:338–47.PubMedCrossRefGoogle Scholar
  20. 20.
    Callahan N, Modesto A, Meira R, Seymen F, Patir A, Vieira AR. Axis inhibition protein 2 (AXIN2) polymorphisms and tooth agenesis. Arch Oral Biol. 2009;54:45–9.PubMedCentralPubMedCrossRefGoogle Scholar
  21. 21.
    Pinarbasi E, Gunes EG, Pinarbasi H, Donmez G, Silig Y. AXIN2 polymorphism and its association with prostate cancer in a Turkish population. Med Oncol. 2011;28:1373–8.PubMedCrossRefGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  • Dan Liu
    • 1
  • Ling Li
    • 1
  • Yuguang Yang
    • 1
  • Wentao Liu
    • 1
  • Jin Wu
    • 1
  1. 1.Department of Medical OncologyCancer Hospital of Harbin Medical UniversityHarbinChina

Personalised recommendations